Masimo Corporation $MASI Stock Position Boosted by Citigroup Inc.

Citigroup Inc. raised its stake in shares of Masimo Corporation (NASDAQ:MASI) by 133.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 116,672 shares of the medical equipment provider’s stock after buying an additional 66,710 shares during the period. Citigroup Inc. owned approximately 0.22% of Masimo worth $17,215,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in MASI. MAI Capital Management increased its stake in shares of Masimo by 176.7% during the second quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 129 shares during the period. Smartleaf Asset Management LLC boosted its stake in Masimo by 80.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 136 shares in the last quarter. Allworth Financial LP increased its position in shares of Masimo by 72.8% during the 2nd quarter. Allworth Financial LP now owns 387 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 163 shares during the period. Quantbot Technologies LP bought a new stake in shares of Masimo in the 2nd quarter worth $86,000. Finally, Hantz Financial Services Inc. lifted its holdings in shares of Masimo by 792.3% in the third quarter. Hantz Financial Services Inc. now owns 580 shares of the medical equipment provider’s stock valued at $86,000 after buying an additional 515 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on MASI shares. Wolfe Research lowered Masimo from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Stifel Nicolaus set a $180.00 price objective on shares of Masimo in a research note on Tuesday, February 17th. Weiss Ratings reissued a “sell (d)” rating on shares of Masimo in a research note on Thursday, January 22nd. Bank of America assumed coverage on shares of Masimo in a research report on Monday, November 17th. They issued a “neutral” rating and a $162.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Monday, December 1st. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Masimo presently has an average rating of “Hold” and an average price target of $181.17.

Masimo Stock Up 0.1%

MASI stock opened at $175.35 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.84 and a quick ratio of 1.92. The firm has a market capitalization of $9.42 billion, a P/E ratio of -16.64, a P/E/G ratio of 1.78 and a beta of 1.26. Masimo Corporation has a 52-week low of $125.94 and a 52-week high of $194.88. The company’s 50 day simple moving average is $143.09 and its 200-day simple moving average is $144.07.

Masimo Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.